Featured Posters & Presentations
Lyfgenia
Renal complications and predictions of chronic renal disease in newborn cohort of patients with homozygous sickle cell disease.
Authors: Soriano M.
Lyfgenia
Development of key criteria for an economic model for a potentially curative one-time treatment for sickle cell disease and evaluation of published models with respect to these criteria.
Authors: Purser M.
Lyfgenia
Outcomes in patients treated with LentiGlobin for sickle cell disease (SCD) gene therapy: Updated results from the phase 1/2 HGB-206 group C study.
Authors: Kanter JA.
Zynteglo
Improvement in erythropoiesis in patients with transfusion-dependent B-thalassemia following treatment with betibeglogene autotemcel (lentiglobin for B-thalassemia) in the Phase 3 HGB-207 study.
Authors: Porter JB.
Zynteglo
Betibeglogene autotemcel (LentiGlobin) in patients with transfusion-dependent β-thalassemia and β0/β 0, β+IVS-I- 110/β+IVS-I-110, or β0/β+IVS-I-110 genotypes: updated results from the HGB-212 study.
Authors: Yannaki E.